36 kDa cell wall Antibody

Shipped with Ice Packs
In Stock

Description

Contextual Analysis of 36 kDa Targets

The 36 kDa size range is observed in both muscle proteins (e.g., Tropomyosin) and stress-induced fungal cell wall components. Key distinctions:

Protein TypeMolecular WeightLocalizationAntibody Example
Tropomyosin36/39 kDaMuscle tissueMA1095
Fungal Stress Proteins30–40 kDaCell wall surfacePga31

Anti-Tropomyosin Antibody MA1095 (36/39 kDa)

Characteristics :

  • Target: Tropomyosin isoforms in muscle tissues (non-cell wall protein)

  • Reactivity: Cross-species (human, mouse, rat)

  • Western Blot: Detects bands at 35–45 kDa (Fig. 1)

  • Applications: Muscle pathology research, not microbial studies

Fungal Cell Wall Antibodies in the 30–40 kDa Range

While no 36 kDa-specific cell wall antibody is documented, related targets include:

A. Candida albicans Pga31

  • Molecular Weight: ~31 kDa

  • Function: β-1,3-glucan-modifying enzyme critical for cell wall integrity

  • Antibodies:

    • 1B11/1G4 scAbs: Bind Pga31 epitopes exposed during caspofungin treatment

    • Reformatted mAbs: Showed 400-fold affinity improvement (EC₅₀: 400 pM)

Cryptococcal Chitooligomer-Binding Antibodies

  • Target: Chitin fragments (3–6 kDa) in Cryptococcus neoformans

  • Antibodies:

    • DD11 IgM: Higher affinity (Kₐ = 5.4 × 10⁴ M⁻¹) than CC5

    • Synergy: Enhanced amphotericin B efficacy by 40% (FII < 1)

Technical Challenges in Cell Wall Antibody Development

  • Epitope Masking: Tight polysaccharide arrays hinder antibody access

  • Immunization Strategies:

    • Shotgun Approach: Crude cell wall extracts improve immunogenicity

    • HTP Platforms: Enable epitope mapping via oligosaccharide microarrays

Key Research Gaps

  • No validated 36 kDa fungal/bacterial cell wall antibody exists in peer-reviewed literature.

  • Anti-Tropomyosin MA1095’s 36 kDa detection is unrelated to microbial targets .

  • Putative cross-reactivity between muscle proteins and microbial antigens remains unexplored.

Future Directions

  • Screen hybridoma libraries against 30–40 kDa fungal cell wall fractions.

  • Apply phage display to isolate antibodies for stress-induced epitopes (e.g., caspofungin-exposed Pga31 ).

Product Specs

Buffer
Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
14-16 weeks lead time (made-to-order)
Synonyms
36 kDa cell wall protein antibody; Fragment antibody
Uniprot No.

Target Background

Subcellular Location
Secreted, cell wall.

Q&A

Here’s a structured collection of FAQs tailored for academic researchers working with 36 kDa cell wall antibodies, incorporating methodological insights and data from peer-reviewed studies:

Advanced Research Questions

How do I resolve discrepancies in 36 kDa antibody reactivity across experimental systems?

  • Analysis Framework:

    • Epitope masking: Pre-treat samples with enzymes (e.g., pectate lyase for plant cell walls) .

    • Glycosylation interference: Use deglycosylation enzymes (e.g., PNGase F) and compare band shifts .

    • Cross-reactivity: Screen against phylogenetically related proteins (e.g., Connexin 36 vs. other connexins) .

What strategies improve antibody performance in non-model plant systems?

  • Experimental Design:

    • Generate phage-display libraries from synchronized cell cultures to enrich target-specific clones .

    • Apply subtractive screening against non-vascular cell wall extracts .

    • Use epitope mapping tools (e.g., LM5/LM6 for polysaccharide motifs) .

How do I validate antibody utility in structural studies of cell wall dynamics?

  • Integrated Workflow:

    • Localization: Combine immunofluorescence with Calcofluor White staining for wall architecture .

    • Quantification: Pair Western blotting with ELISA for absolute antigen levels .

    • Functional assays: Correlate antibody binding with mechanical properties (e.g., tensile strength assays) .

Data Interpretation & Troubleshooting

Why does my antibody detect multiple bands near 36 kDa?

  • Root Cause Analysis:

    • Proteolytic degradation: Add fresh protease inhibitors during extraction .

    • Isoform expression: Test tissues with known isoform dominance (e.g., heart vs. skeletal muscle) .

    • Phosphorylation states: Treat lysates with phosphatases (e.g., λ-PPase) .

How do I address inconsistent immunohistochemistry results?

  • Optimization Steps:

    • Fixation: Compare paraformaldehyde vs. cold methanol effects on epitope preservation .

    • Embedding: Test resin types (e.g., LR White vs. Spurr’s) for epitope accessibility .

    • Antigen retrieval: Use graded KOH (2–24%) to unmask polysaccharide epitopes .

Emerging Methodologies

Can phage display libraries replace hybridoma technology for cell wall antibody development?

  • Comparative Assessment:

ParameterPhage Display Hybridoma
Epitope DiversityBroad (10^6–10^11 clones)Limited by immunization
Development Time6–8 weeks3–6 months
Glycosylation SensitivityHigh (screen under native conditions)Moderate (dependent on immunization)

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.